Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PSNL 
Personalis Inc (PSNL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/13/2025: PSNL (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.62
1 Year Target Price $10.62
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 121.43% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 674.91M USD | Price to earnings Ratio - | 1Y Target Price 10.62 |
Price to earnings Ratio - | 1Y Target Price 10.62 | ||
Volume (30-day avg) 7 | Beta 2.01 | 52 Weeks Range 2.83 - 10.95 | Updated Date 11/13/2025 |
52 Weeks Range 2.83 - 10.95 | Updated Date 11/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.83 |
Earnings Date
Report Date 2025-11-04 | When - | Estimate -0.2763 | Actual -0.24 |
Profitability
Profit Margin -106.92% | Operating Margin (TTM) -160.68% |
Management Effectiveness
Return on Assets (TTM) -20.95% | Return on Equity (TTM) -43.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 602726870 | Price to Sales(TTM) 9.77 |
Enterprise Value 602726870 | Price to Sales(TTM) 9.77 | ||
Enterprise Value to Revenue 8.72 | Enterprise Value to EBITDA -0.03 | Shares Outstanding 88804348 | Shares Floating 52638777 |
Shares Outstanding 88804348 | Shares Floating 52638777 | ||
Percent Insiders 31.28 | Percent Institutions 54.23 |
Upturn AI SWOT
Personalis Inc
Company Overview
History and Background
Personalis, Inc. (PSNL) was founded in 2011 and is based in Menlo Park, California. It focuses on cancer genomics, developing genomic solutions to enable personalized cancer therapies.
Core Business Areas
- Cancer Genomics: Provides comprehensive genomic profiling of cancer samples to identify biomarkers, drug targets, and resistance mechanisms.
- Neoantigen Discovery: Develops platforms for identifying and validating neoantigens, which are unique to individual tumors, for personalized immunotherapies.
- Clinical Trial Services: Offers services to support clinical trials, including patient stratification and biomarker analysis.
Leadership and Structure
John West is the CEO. The company has a typical corporate structure with departments for research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- NeXT Personalu2122: A comprehensive genomic profiling assay for cancer. It sequences the entire genome and transcriptome of a tumor and paired normal sample, providing a detailed picture of the tumor's genetic makeup. Revenue is not explicitly available to the public. Competitors include Foundation Medicine (part of Roche), Caris Life Sciences, and Guardant Health.
- ImmunoID NeXT Platform: A platform for identifying and validating neoantigens. It analyzes tumor samples to identify neoantigens that can be targeted by personalized immunotherapies. Revenue is not explicitly available to the public. Competitors include Gritstone bio and BioNTech.
Market Dynamics
Industry Overview
The cancer genomics market is rapidly growing, driven by advances in sequencing technology and increasing demand for personalized cancer therapies. The market is competitive, with numerous companies offering genomic profiling and neoantigen discovery services.
Positioning
Personalis is positioned as a provider of comprehensive genomic profiling and neoantigen discovery solutions for personalized cancer therapies. Their strength lies in their sophisticated analysis of the whole genome and transcriptome, offering deep insights compared to competitors. However, they are a relatively smaller player compared to Foundation Medicine and Guardant Health.
Total Addressable Market (TAM)
The global cancer genomics market is expected to reach tens of billions of dollars by the end of the decade. Personalis is positioned to capture a share of this market through its NeXT Personal and ImmunoID NeXT Platform but will need to compete with larger, more established players.
Upturn SWOT Analysis
Strengths
- Comprehensive genomic profiling capabilities
- Expertise in neoantigen discovery
- Strong relationships with leading cancer researchers
- Advanced technology platforms
Weaknesses
- High operating expenses
- Dependence on key customers
- Limited commercial reach compared to larger competitors
- Cash burn rate
Opportunities
- Expanding partnerships with pharmaceutical companies
- Increasing adoption of personalized cancer therapies
- Developing new diagnostic and therapeutic applications
- Expansion into international markets
Threats
- Competition from larger, more established players
- Technological advancements by competitors
- Regulatory changes
- Reimbursement challenges for genomic testing
- Economic slowdown
Competitors and Market Share
Key Competitors
- FMI
- CGDX
- GH
Competitive Landscape
Personalis has a technological advantage, offering comprehensive genome sequencing, but lacks the commercial presence of FMI. CGDX is a strong competitor in specific targeted sequencing and diagnostics.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been variable, influenced by partnerships and clinical trial demands.
Future Projections: Future growth projections depend heavily on the expansion of their partnerships with larger pharmaceutical companies and the market penetration of their products.
Recent Initiatives: Recent initiatives likely involve expansion of the NeXT platform with new applications, development of machine learning models to speed the identification of targets, and other innovation activities.
Summary
Personalis presents a mix of promising technology and inherent challenges. Its comprehensive genomic sequencing expertise offers a competitive edge in personalized cancer treatment. The company needs to strategically navigate competitive pressures while expanding its commercial partnerships. Financial prudence is vital to achieving sustainable growth and market share. Success hinges on further innovation and successful commercialization efforts.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry news
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Personalis Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2019-06-20 | President, CEO & Director Mr. Christopher M. Hall | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 228 | Website https://www.personalis.com |
Full time employees 228 | Website https://www.personalis.com | ||
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company has strategic collaboration with Tempus AI, Inc. to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.